Introduction
Chronic lymphocytic leukemia (CLL) is characterized by profound immune dysregulation resulting in significant infection-related morbidity and mortality. 1 Since the 1950s, 2,3 hypogammaglobulinemia has been reported in association with CLL and affects up to 85% of patients during the course of their disease. 4 Deficiencies in IgG and its subclasses, IgA, and IgM may be present. 5 Stage and duration of disease correlate with the severity of hypogammaglobulinemia. 4 Although other immune defects, such as impairments of T-cell function, also contribute to infection risk, CLL patients with lower serum immunoglobulin levels appear to be particularly susceptible to severe and recurrent infections. 6 Multiple mechanisms have been implicated in the development of hypogammaglobulinemia. In co-culture experiments, CLL cells inhibit antibody production by bone marrow plasma cells via Fas/Fas ligand interaction. 7 In addition, newly produced B cells in the peripheral blood are decreased in CLL patients compared to healthy controls, 8 contributing to a smaller pool of antibody-producing cells. T and NK cells from CLL patients also down-regulate antibody secretion by activated B cells from healthy donors in vitro. [9] [10] [11] Moreover, an expanded population of CD30+ T cells commonly found in CLL inhibits isotype switching to IgG and IgA, even in non-clonal B cells. 12 Disease-inherent immunodeficiency is further compounded by treatment. Standard anti-CD20 based chemoimmunotherapy for young, physically fit patients leads to significant neutropenia and infection 13, 14 and does not improve serum immunoglobulin levels, at least in the short-term. 13 The addition of rituximab, although generally well tolerated, has been associated with fatal hepatitis B reactivation and progressive multifocal leukoencephalopathy. 15 In an extended follow-up of 300 patients treated with chemoimmunotherapy, recurrent late cytopenias occurred in 28% and the risk of serious infections remained elevated during the first 2 years of remission. 16 Thus, chemoimmunotherapy causes both short and long-term impairments of the immune system. B-cell receptor (BCR) signaling is critical in normal B lymphopoiesis and has been implicated in the pathogenesis of a number of different B-cell malignancies. 17 In CLL, activation of BCR signaling, particularly within the microenvironment of secondary lymphoid tissues, drives survival and proliferation of tumor cells. 18, 19 Hence, there has been a growing interest in disrupting BCR signal transduction by targeting kinases downstream of the BCR. [20] [21] [22] Ibrutinib, which covalently binds and irreversibly inhibits Bruton's tyrosine kinase (BTK), has demonstrated clinical efficacy in CLL as well as other B-cell malignancies and is approved for second-line treatment of CLL and mantle cell lymphoma, and for front- Patients, material, and methods
Patients
Samples originated from a phase 2, investigator-initiated trial studying ibrutinib 420 mg once daily in patients with treatment naïve and relapsed/refractory CLL ≥ 65 years of age or with TP53 aberration (NCT01500733). 24, 31 The study was approved by an institutional review board and conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice. All patients provided written informed consent.
The study enrolled 86 patients, of whom 2 were excluded from analysis due to enrollment deviation.
Patient characteristics are summarized in Supplemental Polyreactive antibody titers in the sera were determined by a surrogate assay for polyreactivity using dinitrophenol (DNP; Invitrogen, Carlsbad, CA, USA). Two-fold serially diluted serum was incubated on ELISA plates previously coated with 5 µg/ml of DNP. The bound antibody titers were determined by goat anti-human IgM, IgG and IgA coupled with horse radish peroxidase (all from Southern Biotechnology Associates, Birmingham, AL, USA) and developed 2',2'-azino-bis (3-ethylbenzthazoline-6-sulphonic acid).
The polyreactive antibody titer was reported as the reciprocal of the serum dilution above predetermined background activity.
Serum B cell activating factor (BAFF) was measured according to manufacturer's specifications using a bead-based multiplex screening assay from R&D systems (Minneapolis, MN, USA) on a Luminex IS100 instrument (Luminex Corp. Austin, TX, USA). Data were analyzed using Bio-Plex Manager Pro 6.1 analysis software (Bio-Rad, Hercules, CA, USA).
Analysis of normal B cells was performed in the Flow Cytometry Laboratory, Laboratory of Pathology, National Cancer Institute, NIH. Specimens were processed within 12 hours of collection as previously described. 33 Cells were stained with the following antibodies: anti-CD3-V500, CD5-PerCP, CD5-APC, CD5-V450, CD11c-V450, CD14-AH7, CD19-PC7, CD20-PerCP, CD20-AH7, CD22-PE, CD22-PerCP, CD38-V450 CD45-V500, CD79b-PE, CD81-FITC, kappa-m-FITC, kappa-p-APC (polyclonal rabbit antihuman, F(ab')2), lambda-m-PE, and lambda-p-FITC (polyclonal rabbit anti-human, F(ab')2) (all from BD Biosciences, Franklin Lakes, NJ, USA). Specimens were analyzed on a FACS CantoTMII flow cytometer (BD Biosciences) using FCS Express (De Novo Software, Los Angeles, CA, USA). CLL cells were identified as previously described. 34 Normal mature B cells were identified by appropriate levels of CD19, CD20, CD22, CD45, CD38, CD43 and CD81 expression and polyclonal expression of surface light chain immunoglobulin (Supplemental Figure S1 ). B-cell precursors were identified by appropriate levels of 
Statistical analysis
Wilcoxon signed-rank test was used to compare paired longitudinal data. Mann-Whitney U test and Pearson's chi-square test were used to compare continuous and categorical variables between different groups, respectively. The mean number of the infections over time was estimated nonparametrically by the Nelson-Aalen method. 35 Differences in the rate of infection between subgroups were examined using the Cox regression model for recurrent events. 
Results

Change in serum immunoglobulins on ibrutinib
In agreement with previous reports, 23, 29 IgG remained stable during the first 6 months of treatment ( Figure   1A , Table 1 ). However, by 12 months, a slight decrease in IgG was apparent (n = 35, median reduction 4%, P<.0006). This decrease became more profound at 24 months (n = 21, median reduction 23%
[interquartile range (IQR) 9-37%], P<.0001). In 6 of 18 (33%) patients, a previously normal baseline IgG decreased below normal at 24 months. In five patients with follow-up of ≥ 36 months, IgG at 24 and 36 months were similar (median 7.9 and 8.1 g/L, respectively), suggesting that there was no further decline.
In contrast to IgG, we observed an improvement in IgA within 6 months of starting ibrutinib ( Figure 1B , Figure 1C , Table 1 ). At Some CLL clones, particularly those of the IGHV unmutated subtype, express BCR specificity similar to that of B cells producing polyreactive antibodies. 37 Therefore, we evaluated the serum levels of polyreactive antibodies pre-treatment and on ibrutinib and found that both polyreactive IgA and IgM increased over time (P=.01 and P=.03, respectively at 12 months; Figure 1E -F). Since one would expect treatment to decrease polyreactive antibodies if they were derived from CLL cells, this increase may in fact represent the recovery of non-leukemic polyreactive B cells.
Normalization of serum free light chains on ibrutinib
The observed changes in serum immunoglobulins suggest that ibrutinib may affect clonal and non-clonal B cells in opposite ways. We sought to investigate this further by analyzing the serum levels of FLCs.
Patients were divided into two groups based on kappa (κ) or lambda (λ) light chain restriction of their CLL Figure 2A -B, Table 2 ). On IFE, the monoclonal κ FLC was no longer detectable in 4 of 8 (50%) patients following ibrutinib therapy. In contrast, the non-clonal (λ) FLCs increased while on treatment (P=.0002 and P=.0005 at 6 and 12 months, respectively; Figure 2C , Figure 2D -E, Table 2 ). Three patients no longer had a detectable monoclonal λ FLC on IFE. In contrast to the observed increase of λ FLCs in κ -clonal patients, the non-clonal (κ) FLCs in λ -clonal patients remained mostly stable and increased in only a few patients ( Figure 2F , Table 2 ).
Normal B cell recovery in peripheral blood and bone marrow
Given the observed increases in IgA and non-clonal FLCs, we hypothesized that normal B cells may be recovering on ibrutinib therapy. An increase in the percentage of normal B cells was noted at 12 and 24 months on ibrutinib compared to baseline ( Figure 3A-B) . However, the normal B-cell count remained abnormally low in the majority of patients ( Figure 3C ), even in those with effective control of their CLL who achieved a normal or near-normal absolute lymphocyte count ( Figure 3D ). In 3 patients, the normal Bcell count was within the reference range at 12 months. While normal B cells in circulation were undetectable in 25 of 67 (37%) patients at 12 months, this was only the case in 6 of 38 (16%) patients at 24 months. Compared to those with relapsed/refractory disease, treatment naïve patients were more likely to have normal B cells at 12 months (29% versus 78%, P<.0001). At 24 months, this difference was no longer observed, suggesting that the effect of prior therapies may delay, but does not preclude, B-cell reconstitution on ibrutinib.
Next, we analyzed available bone marrow aspirates by flow cytometry to corroborate our observations in the peripheral blood. We found an upward trend in the percentage of normal B cells (Table 3) resembled that of healthy donors (Supplemental Figure S4A) . 38 However, the B-cell subsets were abnormally distributed in the remaining 3 patients (Supplemental Figure S4B of representative case).
Thus, while there is an overall increase in normal B cells in ibrutinib-treated patients, the recovery of specific B-cell subsets can differ from healthy individuals.
One reason for the low numbers of normal B cells in patients with CLL may be a competition for critical survival factors. In particular, BAFF is required for B-cell survival and maturation 39 and is diminished in CLL patients. 40, 41 Serum BAFF levels are inversely correlated with the number of B cells expressing BAFF receptor (BAFF-R), including CLL cells. 40 In agreement with previous reports, pre-treatment serum BAFF levels in our patients were substantially lower than in healthy controls. 39 Following initiation of ibrutinib, serum BAFF increased to normal levels ( Figure 3E ).
Infection risk
Next, we sought to explore the contribution of changes in immunoglobulins and normal B cells on the risk of infection in our patients. At a median follow-up of 27.8 months, 69 of 84 (82%) patients developed a total of 177 infections. These included 25 grade 3-4 infections in 20 (24%) patients and four grade 5 events. Infections were more frequent during the first 6 months with an average rate of 16.3 infections per 100 patient-months compared to 6.9 thereafter (Supplemental Figure S4A) . Respiratory tract infections were the most common (65%), followed by gastrointestinal or genitourinary (16%) and skin (13%)
infections. Patients with relapsed/refractory CLL had more infections of any grade than previously untreated patients (risk ratio1.58, P=.002; Figure 4A ). Prior treatment was also associated with a higher rate of grade ≥ 3 infections (risk ratio 2.23, P=.03; Supplemental Figure S4B ).
Using the improvement in IgA as a measure of immune reconstitution, we compared infection rates in patient groups divided by the median fold-change in IgA at 12 months compared to baseline. Patients with ≥ 50% increase in IgA had a lower rate of infection (risk ratio 0.61, P=.03; Figure 4B ) than patients with <50% increase in IgA. The difference remained significant (P=.03) after adjustment for prior treatment status. In contrast, baseline immunoglobulin levels and changes in IgG and IgM were not correlated with infection risk (Supplemental Table S2 ).
Discussion
The essential role of BTK in B-cell maturation and immunoglobulin production is demonstrated by loss-offunction mutations that cause X-linked agammaglobulinemia. 28 Given that ibrutinib leads to sustained inhibition of BTK, clinical trials investigating its use have monitored immunoglobulin levels in patients on treatment. A consistent but surprising observation has been the increase in IgA seen in these studies. 23, 29 For personal use only. Multiple factors likely contribute to the improvement in specific immunoglobulin classes. The rapidity of increase in IgA suggests that pre-existing antibody-producing cells may be secreting more immunoglobulins, whilst CLL cells, which impair immunoglobulin production, 7, 8 are removed by ibrutinib.
Additionally, stimulatory signals provided by increasing BAFF levels may promote the emergence of normal B cells. In agreement with previous reports, we found that serum BAFF levels were suppressed in CLL patients at baseline 40, 41 and rapidly increased to normal levels during treatment with ibrutinib. BAFF binds to BAFF-R, the cognate receptor on B cells, to activate the alternative NF-κB pathway and drive cell survival and proliferation. 42 BAFF has been shown to support CLL cell survival in vitro, 43, 44 raising the question whether BAFF signaling could support the survival of remaining CLL cells. However, ibrutinib was previously shown to inhibit BAFF-R signaling 45 and analyses of CLL cells from patients receiving ibrutinib demonstrated sustained inhibition of BCR and NF-кB signaling and tumor proliferation.
46
The risk of infection in CLL patients is associated with the severity of hypogammaglobulinemia and is somewhat mitigated by IVIG replacement. 1, 6 We observed that among our patients, those with an increase in IgA of ≥ 50% above baseline had a lower rate of infections than those with an increase of <50%, even after adjustment for prior treatment status. Furthermore, prior treatment was associated with a lower baseline IgA, but not the change in IgA on ibrutinib. Secretory IgA coats mucosal surfaces where it binds and prevents epithelial adherence and translocation of pathogens. 47 Since most patients with IgA deficiency are asymptomatic, the role of IgA in mucosal immunity is often considered redundant. 47 However, when multiple facets of the immune system are disrupted, such as in CLL, 1 IgA may have a =.028 P Figure 4 
